Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,010.31
-4.18 (-0.41%)
At close: Dec 5, 2025, 4:00 PM EST
1,014.40
+4.09 (0.40%)
After-hours: Dec 5, 2025, 7:59 PM EST
Eli Lilly Revenue
Eli Lilly had revenue of $17.60B in the quarter ending September 30, 2025, with 53.87% growth. This brings the company's revenue in the last twelve months to $59.42B, up 45.41% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$59.42B
Revenue Growth
+45.41%
P/S Ratio
15.27
Revenue / Employee
$1,264,251
Employees
47,000
Market Cap
904.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
LLY News
- 12 hours ago - Meet the Supercharged Growth Stock That Could Join Apple, Nvidia, Microsoft, and Alphabet in the $2 Trillion Club by 2028 - The Motley Fool
- 21 hours ago - With Netflix's 10-for-1 Stock Split Complete, Here Are 3 Growth Stocks to Buy in December That Could Issue Stock Splits in 2026 - The Motley Fool
- 2 days ago - Companies Cut Prices For Blockbuster Weight-Loss Drugs - Forbes
- 2 days ago - 1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year - The Motley Fool
- 2 days ago - U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor - PRNewsWire
- 2 days ago - GXP-Storage Appoints Former Eli Lilly Global Clinical Research Executive Chris Otto to Board of Directors - Business Wire
- 2 days ago - 2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years - The Motley Fool
- 3 days ago - Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha